Genia Long
Impact in
- Family Practice top 10%
- Medication Adherence and Compliance
- Economics and Econometrics top 5%
- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Innovation Policy and R&D
Papers in
-
- Health Systems, Economic Evaluations, Quality of Life 14
- Pharmaceutical Economics and Policy 14
- Economic and Financial Impacts of Cancer 2
-
- Biosimilars and Bioanalytical Methods 5
- Co-authors
- Henry G. Grabowski (10 shared papers)Richard Mortimer (7 shared papers)Iain Cockburn (1 shared paper)Joseph A. DiMasi (2 shared papers)David Cutler (4 shared papers)Ernst R. Berndt (3 shared papers)Alicia Sasser (2 shared papers)Pierre Y. Crémieux (2 shared papers)
- Journals
- Journal of Medical Economics (6 papers)Health Affairs (5 papers)PharmacoEconomics (1 paper)Nature Reviews Drug Discovery (1 paper)Expert Review of Clinical Pharmacology (1 paper)
- Partner nations
- United StatesSingaporeFrance
In The Last Decade
Genia Long
18 papers receiving 367 citations
Peers
Comparison fields: 5 of 77
- Family Practice 27
- Economics and Econometrics 294
- Management of Technology and Innovation 66
- Pharmacology 50
- Immunology 93
Countries citing papers authored by Genia Long
This map shows the geographic impact of Genia Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Genia Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Genia Long more than expected).
Fields of papers citing papers by Genia Long
This network shows the impact of papers produced by Genia Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Genia Long. The network helps show where Genia Long may publish in the future.
Co-authors
The 20 scholars most cited alongside Genia Long, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 90 | |
| 2 | 2006 | 61 | |
| 3 | 2016 | 52 | |
| 4 | 2013 | 49 | |
| 5 | 2015 | 39 | |
| 6 | 2011 | 25 | |
| 7 | Implementation of the biosimilar pathway: economic and policy issues. | 2011 | 16 |
| 8 | 2021 | 14 | |
| 9 | 2010 | 11 | |
| 10 | 2024 | 6 | |
| 11 | 2014 | 6 | |
| 12 | 2013 | 5 | |
| 13 | 2024 | 4 | |
| 14 | 2007 | 4 | |
| 15 | 2021 | 3 | |
| 16 | 2019 | 3 | |
| 17 | The Impact of Antihypertensive Drugs on the Number and Risk of Death, Stroke and Myocardial Infarction in the United States | 2006 | 2 |
| 18 | 2020 | 1 | |
| 19 | 2025 | 0 |
About Genia Long
Genia Long is a scholar working on Economics and Econometrics, Immunology, General Health Professions, Cardiology and Cardiovascular Medicine and Pharmacology, having authored 19 papers that have together received 391 indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (14 papers), Pharmaceutical Economics and Policy (14 papers), Biosimilars and Bioanalytical Methods (5 papers), Blood Pressure and Hypertension Studies (3 papers), Pharmaceutical industry and healthcare (3 papers), Global Health Care Issues (3 papers), Economic and Financial Impacts of Cancer (2 papers) and Biotechnology and Related Fields (2 papers). The work is most often cited by research in Family Practice (27 citations), Economics and Econometrics (294 citations), Management of Technology and Innovation (66 citations), Pharmacology (50 citations) and Immunology (93 citations). Genia Long has collaborated with scholars based in United States, Singapore and France. Frequent co-authors include Henry G. Grabowski, Richard Mortimer, Iain Cockburn, Joseph A. DiMasi, David Cutler, Ernst R. Berndt, Alicia Sasser, Pierre Y. Crémieux, Andrée-Anne Fournier and Noam Y. Kirson. Their work appears in journals such as Journal of Medical Economics, Health Affairs, PharmacoEconomics, Nature Reviews Drug Discovery and Expert Review of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.